Patents by Inventor Jeff L. Ellsworth

Jeff L. Ellsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10728112
    Abstract: Various embodiments of a system and method for tracking service requests are described. Embodiments may include call tree generation logic configured to receive multiple request identifiers associated with a respective one of multiple service requests. Each given request identifier may include an origin identifier, a depth value, and a request stack comprising one or more interaction identifiers. The call tree generation logic may also be configured to, based on multiple request identifiers that each include an origin identifier associated with a particular root request, generating a data structure that specifies a hierarchy of services called to fulfill that particular root request. Based on one or more of the interaction identifiers and one or more of the depth values, the generated data structure may specify for each given service of the hierarchy: a parent service that called the given service, and one or more child services called by the given service.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: July 28, 2020
    Assignee: Amazon Technologies, Inc.
    Inventors: Jeff B. Beal, Alan Stuart Robbins, Jeromey R. Goetz, Brandon William Porter, Grant Alexander MacDonald McAlister, Joseph L. Ellsworth
  • Publication number: 20200131245
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Application
    Filed: January 8, 2020
    Publication date: April 30, 2020
    Applicant: ZYMOGENETICS, INC.
    Inventors: Carl W. BIRKS, Brian A.. FOX, Mark W. RIXON, Jeff L. ELLSWORTH
  • Patent number: 10570187
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: February 25, 2020
    Assignee: ZymoGenetics, Inc.
    Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • Publication number: 20170226184
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Application
    Filed: April 21, 2017
    Publication date: August 10, 2017
    Inventors: Carl W. BIRKS, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • Patent number: 9663566
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: May 30, 2017
    Assignee: ZymoGenetics, Inc.
    Inventors: Carl W Birks, Brian A Fox, Mark W Rixon, Jeff L Ellsworth
  • Publication number: 20140107034
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Application
    Filed: December 17, 2013
    Publication date: April 17, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Carl W. BIRKS, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • Patent number: 8658766
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Grant
    Filed: June 29, 2009
    Date of Patent: February 25, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • Patent number: 8507430
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.
    Type: Grant
    Filed: April 16, 2008
    Date of Patent: August 13, 2013
    Assignee: ZymoGenetics, Inc.
    Inventor: Jeff L. Ellsworth
  • Patent number: 8084426
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Grant
    Filed: May 20, 2010
    Date of Patent: December 27, 2011
    Assignee: ZymoGenetics, Inc.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Publication number: 20110217291
    Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.
    Type: Application
    Filed: June 29, 2009
    Publication date: September 8, 2011
    Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
  • Publication number: 20100291212
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Application
    Filed: May 20, 2010
    Publication date: November 18, 2010
    Applicant: ZYMOGENETICS, INC.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Patent number: 7749965
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: July 6, 2010
    Assignee: ZymoGenetics, Inc.
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Publication number: 20080219978
    Abstract: Disclosed are soluble Fc?RIA polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble Fc?RIA polypeptides.
    Type: Application
    Filed: January 23, 2008
    Publication date: September 11, 2008
    Inventor: Jeff L. Ellsworth
  • Publication number: 20080193425
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.
    Type: Application
    Filed: April 16, 2008
    Publication date: August 14, 2008
    Inventor: Jeff L. Ellsworth
  • Publication number: 20080193501
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, bone, and nervous tissue, resulting in repair of diseased tissue. When an IL-1 antagonist is administered in addition to FGF18, the effects on the IL-1 mediated disease and also, the effect on cartilage, bone, and nervous cell proliferation, are found to be greater than administration of FGF18 or the IL-1 antagonist alone. The present invention encompasses a pharmaceutical composition that combines FGF18 with IL-1 antagonist and methods of treating IL-1 mediated disease using this pharmaceutical composition.
    Type: Application
    Filed: April 15, 2008
    Publication date: August 14, 2008
    Inventors: Emma E. Moore, Jeff L. Ellsworth
  • Publication number: 20040136970
    Abstract: FGF18 is known to stimulate the proliferation of chondrocytes, resulting in increased cartilage formation. When hyaluronic acid is administered in addition to FGF18, the effects on chondrocyte proliferation and production of matrix were found to be greater than administration of FGF18 or hyaluronic acid alone.
    Type: Application
    Filed: October 7, 2003
    Publication date: July 15, 2004
    Inventor: Jeff L. Ellsworth
  • Publication number: 20030023067
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zfsta2, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-&bgr; family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta2 polypeptides.
    Type: Application
    Filed: December 6, 2001
    Publication date: January 30, 2003
    Inventors: Darrell C. Conklin, Jeff L. Ellsworth
  • Patent number: 6498235
    Abstract: The present invention relates to zpep10 polypeptides and polynucleotides encoding the same. Zpep10 polypeptide is a testis-specific membrane glycoprotein. Zpep10 polypeptides would be useful for modulating spermatogenesis and egg-sperm interaction and would be useful to study or modulate these functions in in vitro or in vivo systems. The present invention also includes antibodies to the zpep10 polypeptides.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: December 24, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Christopher S. Piddington, Jeff L. Ellsworth
  • Publication number: 20020102704
    Abstract: The present invention relates to zpep10 polypeptides and polynucleotides encoding the same. Zpep10 polypeptide is a testis-specific membrane glycoprotein. Zpep10 polypeptides would be useful for modulating spermatogenesis and egg-sperm interaction and would be useful to study or modulate these functions in in vitro or in vivo systems. The present invention also includes antibodies to the zpep10 polypeptides.
    Type: Application
    Filed: February 20, 2001
    Publication date: August 1, 2002
    Applicant: ZymoGenetics, Inc.
    Inventors: Paul O. Sheppard, Christopher S. Piddington, Jeff L. Ellsworth
  • Patent number: 6355788
    Abstract: The present invention relates to polynucleotide and polypeptide molecules for zfsta2, a novel member of the follistatin family. The polypeptides, and polynucleotides encoding them are useful for binding to members of the TGF-&bgr; family and mediating central nervous system, reproductive, hematopoietic and bone-related activities. The present invention also includes antibodies to the zfsta2 polypeptides.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: March 12, 2002
    Assignee: ZymoGenetics, Inc.
    Inventors: Darrell C. Conklin, Jeff L. Ellsworth